Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) includes many mature B-cell, T-cell and NK-cell cancers, as well as precursor lymphoblastic lymphomas that follow different treatment pathways. Disease may arise in lymph nodes, the spleen, marrow, skin, stomach, brain or other organs; a mass outside a lymph node can still be lymphoma.

Modern classifications integrate tissue appearance, immune markers, clinical setting and selected genetics. The label “NHL” on a referral is not enough to choose chemotherapy, CAR-T or a targeted medicine. Ask for the final entity name and whether the diagnosis is provisional.

An adequate biopsy allows the pathologist to see tissue architecture and identify malignant cells. Flow cytometry, immunohistochemistry, FISH and sequencing answer different questions; not everyone needs every test. Protein expression and a gene rearrangement are different findings even when they share a name.

Keep the complete report and access to slides or blocks. A review can be especially useful for rare disease, an unexpected clinical course or a treatment-changing molecular result. Steroids before a planned biopsy can alter findings; discuss timing with the team unless urgent stabilization is required.

The examples below show why treatment cannot be selected from the umbrella name alone. A disease can behave differently from its usual pattern, particularly after transformation or relapse.

Continue with the guide matching the final pathology.

In selected asymptomatic, low-burden indolent lymphoma, planned observation can avoid treatment toxicity without forfeiting a useful treatment window. Follow-up reviews symptoms, examination, blood counts and disease burden. It is an active plan with reasons to start treatment, not abandonment of care.

Organ compression, symptomatic bulky disease, worsening blood counts from lymphoma or significant constitutional symptoms can change the decision. Aggressive lymphomas usually require prompt treatment; Burkitt lymphoma and threatening organ involvement can be emergencies. Do not infer urgency from stage alone.

Stage describes distribution, while prognostic scores incorporate disease-specific factors such as age, LDH, sites and health. PET/CT is useful for many FDG-avid subtypes; some indolent diseases need other assessments. Bone marrow sampling is used when it can answer a relevant question, rather than as an identical requirement for every lymphoma.

Some aggressive lymphomas can be cured even when widespread. Many advanced indolent lymphomas are managed through repeated periods of disease control, while localized disease can sometimes receive definitive local treatment. Ask the team to name the goal before comparing response percentages from different studies.

Anti-CD20 antibodies, chemotherapy, radiation and selected targeted drugs have different roles across B-cell diseases. CD19 CAR-T and CD20-directed bispecific antibodies are important in eligible relapsed B-cell lymphomas, but their product labels specify subtype and previous treatment. A recent approval in follicular lymphoma does not automatically apply to DLBCL.

T-cell and NK-cell lymphomas need their own pathways; treatments may depend on CD30, ALK, viral association or the exact entity. Nasal NK/T-cell lymphoma commonly requires an asparaginase-based strategy rather than simply applying a B-cell regimen. Transplantation also serves different purposes in different subtypes.

Availability varies between countries. For example, a combination may have a European indication while a related US label is narrower. A treatment review should establish the actual product, local indication, eligibility and logistics rather than promise that every new lymphoma drug is accessible.

A residual lump does not necessarily contain active lymphoma, and PET uptake can reflect inflammation. Conversely, one rapidly growing lesion in otherwise stable indolent disease can signal transformation. When feasible, biopsy the clinically concerning site before changing to an aggressive treatment pathway.

At relapse, treatment selection considers how long the last remission lasted, which targets and drug classes have already been used, organ reserve and the feasibility of transplant or cellular therapy. Referral before several additional salvage courses can preserve options in diseases where early CAR-T assessment is appropriate.

Screening for hepatitis B before systemic therapy is particularly important when anti-CD20 treatment or transplantation is planned. Past infection can reactivate; antiviral prophylaxis and monitoring depend on the result and regimen. Vaccination, infection prevention and immunoglobulin assessment may also matter.

Rapid tumor killing can cause tumor lysis syndrome in high-risk disease. The team may plan hydration, laboratory monitoring and preventive medicines before treatment. During care, fever, new confusion, breathing difficulty or rapidly worsening swelling needs prompt medical contact.

Bring pathology material, PET/CT images, the full treatment timeline, response dates, prior severe toxicities and infection results. Ask which finding actually changes the plan, whether more tissue is needed and whether the intended goal is cure, long-term control or relief of symptoms.